Almost 50 percent of drugs that are currently on the market target G-protein coupled receptors (GPCRs). But Stuart Maudsley, head of the receptor pharmacology unit at the National Institute of Aging's Laboratory of Neurosciences, thinks that medical research has only scratched the surface of their therapeutic possibilities.